Research Article
Mucinous Histology, BRCA1/2 Mutations, and Elevated Tumor Mutational Burden in Colorectal Cancer
Table 4
Prospective cohort patients’ characteristics.
| | | Adenocarcinoma (n = 40) | Mucinous (n = 30) |
| | Sex | | | | Female | 23 (57.5%) | 12 (40.0%) | | Male | 17 (42.5%) | 18 (60.0%) |
| | Age at diagnosis | | | | Mean (SD) | 59.1 (13.8) | 60.2 (14.7) | | Mean (min, max) | 60.0 (20.0, 86.0) | 63.5 (22.0, 78.0) |
| | Ethnic origin | | | | Arab | 9 (22.5%) | 6 (20.0%) | | Jewish-Ashkenazi | 16 (40.0%) | 15 (50.0%) | | Jewish-non-Ashkenazi | 12 (30.0%) | 7 (23.3%) | | Missing | 3 (7.5%) | 2 (6.7%) |
| | Family breast history | | | | No | 33 (82.5%) | 23 (76.7%) | | Yes | 7 (17.5%) | 7.(23%) |
| | Previous malignancy | | | | No | 36 (90.0%) | 26 (86.7%) | | Yes | 4 (10.0%) | 4 (13.3%) |
| | Stage at diagnosis | | | | I | 3 (7.5%) | 0 (0%) | | II | 4 (10.0%) | 5 (16 7%) | | III | 10 (25.0%) | 13 (43 3%) | | IV | 23 (57.5%) | 11 (36 7%) | | Missing | 0.(0%) | 1 (3.3%) |
| | Primary tumor site | | | | Left | 25 (65.5%) | 18 (60.0%) | | Right | 10.(25.0%) | 11 (36.7%) | | Missing | 5 (12.5%) | 1 (3.3%) |
| | Metastases primary site | | | | Abdomen | 4 (10.0%) | 6 (20.0%) | | Distant | 4 (10.0%) | 3 (10.0%) | | Liver | 22 (55.0%) | 6 (20.0%) | | Pelvis | 3 (7.5%) | 4 (13.3%) | | Missing | 7 (17.5%) | 11 (36.7%) |
| | Surgery | | | | No | 4 (10.0%) | 6 (20.0%) | | Yes | 34 (85.0%) | 23 (76.7%) | | Missing | 2 (5.0%) | 1 (3.3%) |
| | Adjuvant treatment | | | | FOLFOX | 6 (15.0%) | 7 (23.3%) | | None | 22 (55.0%) | 12 (40.0%) | | Oxaliplatin, Fluorouracil | 0 (0%) | 1 (3.3%) | | XELODA | 1 (2.5%) | (2.6.7%) | | XELOX | 3 (7.5%) | 7 (23.3%) | | Missing | 8 (20.0%) | 1 (3.3%) |
|
|
